<DOC>
	<DOCNO>NCT01242397</DOCNO>
	<brief_summary>The purpose study show CRT ( Cardiac Resynchronization Therapy ) pace patient severe functional MR ( Mitral Regurgitation ) currently indicate CRT demonstrate chronic benefit MR reduction ( via echo measure MR/LA area ERO per American Society ECHO guideline ) show CRT pace safe patient .</brief_summary>
	<brief_title>Mitral Insufficiency Reduction With Biventricular Pacing</brief_title>
	<detailed_description>Approximately 50 patient randomize , follow analyzed prospective study . Patients meet inclusion exclusion criterion enrol implant CRT system . Baseline evaluation , include clinical symptom evaluation echocardiogram , perform time randomization , occur soon device implant possible later 2 week post -implant . The baseline echocardiogram acquire prior device program randomized setting . Repeat echocardiogram schedule follow-up evaluation perform end 3 month crossover period .</detailed_description>
	<mesh_term>Mitral Valve Insufficiency</mesh_term>
	<criteria>Patient least 18 year age Patients moderatetosevere severe functional MR. EROA &gt; 40 mm2 MR/LA &gt; 40 % ( severe ) 30 ≤ EROA ≤ 40 mm2 30 ≤ MR/LA ≤ 40 % ( moderatetosevere ) Baseline rate 5090 beat per minute ( patient sinus rhythm ) AF QRS &lt; 120 m LVEF &lt; 35 % Willing sign inform consent On standard stable heart failure medical regimen ( beta blocker ACEI ARBs ) least 1 month randomization , tolerate Patient ability understand requirement study , include consent use disclosure researchrelated information Patient ability comply study procedure protocol , include require study visit candidate CRT previously implant CRT device previously implant implantable pulse generator ( IPG ) implantable cardioverter defibrillator ( ICD ) least 10 % pace right ventricle patient life expectancy &lt; 6 month patient pregnant significant aortic stenosis uncontrolled hypertension mitral valve stenosis severe mitral valve calcification rupture chordae tendinae papillary muscle mitral valve leaflet disorder ( i.e . endocarditis , lupus , tumor , rheumatic heart disease ) chronic mitral leaflet degeneration ( ie . Marfans ) previous valve replacement surgery IV inotropes IV vasodilator candidate mitral valve repair replacement surgery within next 6 month patient inhospital acute coronary syndrome ( ACS ) ( NSTEMI/STEMI ) prior randomization patient plan elective percutaneous coronary intervention ( PCI ) noncardiac surgery prior randomization patient currently enrol investigational drug device study patient clinically unstable per PI assessment</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2009</verification_date>
</DOC>